^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TIM-3 antagonist

    Related drugs:
    21d
    TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal. (PubMed, Cancer Cell Int)
    We examine the current landscape of TIM-3-targeted agents, from monoclonal antibodies like sabatolimab to bispecifics and CAR-T cells, and critically evaluate rational combination strategies with hypomethylating agents, venetoclax, and other immunotherapies. Finally, we discuss the challenges of patient stratification, resistance mechanisms, and on-target toxicity, outlining a roadmap for converting the multifaceted biology of TIM-3 into transformative clinical benefit for AML patients.
    Review • Journal • IO biomarker
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Venclexta (venetoclax) • sabatolimab (MBG453)
    2ms
    TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, University of Hawaii | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    3ms
    ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial (clinicaltrials.gov)
    P1/2, N=3, Active, not recruiting, M.D. Anderson Cancer Center | N=12 --> 3 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    azacitidine • sabatolimab (MBG453)
    3ms
    MBG453 in Lower Risk MDS (clinicaltrials.gov)
    P2, N=10, Terminated, Massachusetts General Hospital | N=20 --> 10 | Trial completion date: Nov 2026 --> Nov 2025 | Active, not recruiting --> Terminated; The trial closed early due to changes in support for the study drug.
    Enrollment change • Trial completion date • Trial termination
    |
    Chr del(5q)
    |
    sabatolimab (MBG453)
    5ms
    Dostarlimab and Cobolimab in Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Meghan Shea | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    7ms
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=83, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jan 2032 --> Oct 2026 | Trial primary completion date: Jan 2032 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    8ms
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=463, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    8ms
    Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (clinicaltrials.gov)
    P1, N=60, Completed, Tesaro, Inc. | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Zejula (niraparib) • albumin-bound paclitaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    8ms
    MBG453 in Lower Risk MDS (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Nov 2026 | Trial primary completion date: Jun 2024 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Chr del(5q)
    |
    sabatolimab (MBG453)
    9ms
    COSTAR Lung: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (clinicaltrials.gov)
    P3, N=758, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2025 --> Mar 2027
    Trial completion date
    |
    docetaxel • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    9ms
    Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    spartalizumab (PDR001) • sabatolimab (MBG453)